Panagiotis Katsaounis

Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

Luis Paz‐Ares, Óscar Juan, Giannis Mountzios et al. · Journal of Clinical Oncology · 2024 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17

Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group

Filippos Koinis, Sofia Agelaki, V. Karavassilis et al. · British Journal of Cancer · 2017 · 43 citations · Full text

Medicine, Oncology, Pharmacology +17

Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)

Dimitriοs Mavroudis, Alexios Matikas, N. Malamos et al. · Annals of Oncology · 2016 · 33 citations

Medicine, Oncology, Pharmacotherapy +16

A multicentre phase II trial of cabazitaxel in patients with advanced non-small-cell lung cancer progressing after docetaxel-based chemotherapy

Alexios Matikas, Filippos Koinis, Nikolaos Kentepozidis et al. · British Journal of Cancer · 2016 · 29 citations · Full text

Medicine, Oncology, Pharmacology +13

Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

Panagiotis Katsaounis, Sofia Agelaki, E. Kontopodis et al. · Cancer Chemotherapy and Pharmacology · 2015 · 22 citations

Medicine, Oncology, Pharmacology +14